Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Morelon

Showing results (181-190 of 209) with videos related to

Pageof 21
Sort By:
Transplant International : Official Journal of the European Society for Organ Transplantation|April 13, 2020
An extension of the RITUX-ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantationElodie Bailly, Simon Ville, Gilles Blancho, et al.
BMJ (Clinical Research Ed.)|August 2, 2015
Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort studyOlivier Aubert, Nassim Kamar, Dewi Vernerey, et al.
Transplantation|November 12, 2015
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled TrialBénédicte Sautenet, Gilles Blancho, Mathias Büchler, et al.
BJU International|June 11, 2021
Kidney transplantation from expanded criteria donors: an increased risk of urinary complications - the UriNary Complications Of Renal Transplant (UNyCORT) studyBenoit Mesnard, Maxime Leroy, James Hunter, et al.
Kidney International|April 9, 2019
Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppressionRenaud Snanoudj, Nassim Kamar, Elisabeth Cassuto, et al.
The Lancet. Diabetes & Endocrinology|May 20, 2018
Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trialSandrine Lablanche, Marie-Christine Vantyghem, Laurence Kessler, et al.
Anaerobe|March 11, 2017
Factors associated with Clostridium difficile infection: A nested case-control study in a three year prospective cohortNagham Khanafer, Philippe Vanhems, Frédéric Barbut, et al.
The New England Journal of Medicine|December 14, 2007
Outcomes 18 months after the first human partial face transplantationJean-Michel Dubernard, Benoit Lengelé, Emmanuel Morelon, et al.
The Journal of Clinical Investigation|May 28, 2025
Chemotaxis overrides the killing response in alloreactive CTLs, providing vascular immune privilege during cellular rejectionThomas Barba, Martin Oberbarnscheidt, Gregory Franck, et al.
Transplantation Direct|May 1, 2018
Poor Patient and Graft Outcome After Induction Treatment by Antithymocyte Globulin in Recipients of a Kidney Graft After Nonrenal Organ TransplantationHoa Le Mai, Michèle Treilhaud, Shani Leviatan Ben-Arye, et al.
Pageof 21

Showing results (181-190 of 209) with videos related to

Sort By:
Pageof 21
Transplant International : Official Journal of the European Society for Organ Transplantation|April 13, 2020
An extension of the RITUX-ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantationElodie Bailly, Simon Ville, Gilles Blancho, et al.
BMJ (Clinical Research Ed.)|August 2, 2015
Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort studyOlivier Aubert, Nassim Kamar, Dewi Vernerey, et al.
Transplantation|November 12, 2015
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled TrialBénédicte Sautenet, Gilles Blancho, Mathias Büchler, et al.
BJU International|June 11, 2021
Kidney transplantation from expanded criteria donors: an increased risk of urinary complications - the UriNary Complications Of Renal Transplant (UNyCORT) studyBenoit Mesnard, Maxime Leroy, James Hunter, et al.
Kidney International|April 9, 2019
Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppressionRenaud Snanoudj, Nassim Kamar, Elisabeth Cassuto, et al.
The Lancet. Diabetes & Endocrinology|May 20, 2018
Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trialSandrine Lablanche, Marie-Christine Vantyghem, Laurence Kessler, et al.
Anaerobe|March 11, 2017
Factors associated with Clostridium difficile infection: A nested case-control study in a three year prospective cohortNagham Khanafer, Philippe Vanhems, Frédéric Barbut, et al.
The New England Journal of Medicine|December 14, 2007
Outcomes 18 months after the first human partial face transplantationJean-Michel Dubernard, Benoit Lengelé, Emmanuel Morelon, et al.
The Journal of Clinical Investigation|May 28, 2025
Chemotaxis overrides the killing response in alloreactive CTLs, providing vascular immune privilege during cellular rejectionThomas Barba, Martin Oberbarnscheidt, Gregory Franck, et al.
Transplantation Direct|May 1, 2018
Poor Patient and Graft Outcome After Induction Treatment by Antithymocyte Globulin in Recipients of a Kidney Graft After Nonrenal Organ TransplantationHoa Le Mai, Michèle Treilhaud, Shani Leviatan Ben-Arye, et al.
Pageof 21